CStone Pharmaceuticals
HKEX:2616
CStone Pharmaceuticals
HKEX:2616
Price:
1.1 HKD
1.85%
Market Closed
Updated:
May 7, 2024
Section:
Relative Value
The Relative Value of one
CStone Pharmaceuticals
stock under the Base Case scenario is
4.87
HKD.
Compared to the current market price of 1.1 HKD,
CStone Pharmaceuticals
is
Undervalued by 77%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Relative Value
Base Case
4.87
HKD
Undervaluation 77%
Valuation Multiples
Multiples Across Competitors
Competitors Multiples
CStone Pharmaceuticals Competitors
CStone Pharmaceuticals Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
|
CStone Pharmaceuticals
HKEX:2616
|
1.4B HKD | 2.8 | -3.5 | -0.9 | -0.9 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
288.1B USD | 5.3 | 59.8 | 13 | 19.8 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
162.1B USD | 5.5 | 43.1 | 18.3 | 30.1 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
105.9B USD | 8.1 | 27.4 | 22.2 | 24.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
104.8B USD | 10.7 | 29.1 | 23.2 | 24.3 | |
| AU |
|
CSL Ltd
ASX:CSL
|
135.1B AUD | 6.3 | 36.2 | 21.9 | 27.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
81.7B USD | 3 | 169.1 | 6.8 | 8.9 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
46B USD | 8.9 | -7.7 | -8.3 | -7.4 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
31.9B USD | 3.3 | 27.2 | 14 | 17.5 | |
| KR |
|
Celltrion Inc
KRX:068270
|
40.3T KRW | 18.5 | 75.2 | 46 | 63.3 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
